Cannabinoid agonist HU-210 reduced sucrose consumption in rats through CB1 receptor-mediated motor impairment | Research

The takeaway

The cannabinoid agonist HU-210 paradoxically reduced sucrose intake in rats by impairing the motor mechanics of licking rather than reducing reward value, an effect blocked by rimonabant.

Appetite researchers, behavioral pharmacologists studying cannabinoid effects

HU-210 impaired motor mechanics of licking; rimonabant reduced apparent reward value

What the researchers found

HU-210 reduced licking by decreasing burst number and intra-burst lick rate (a motor competence index). These effects were antagonized by rimonabant (CB1 antagonist), confirming CB1 dependence. Rimonabant at 0.5 mg/kg decreased burst number late in sessions, resembling reward devaluation, suggesting it reduced "liking."

Why it matters

Understanding how cannabinoids affect feeding behavior at the microstructural level helps separate reward effects from motor effects, which has implications for understanding both appetite regulation and cannabinoid side effects.

The numbers in context

HU-210: 25, 50, 100 ug/kg. Rimonabant: 0.5, 1 mg/kg. HU-210 reduced both burst number and intra-burst lick rate. Rimonabant at 0.5 mg/kg reduced burst number late in session.

How the study worked

Two experiments analyzing the microstructure of licking for 10% sucrose in 30-minute sessions. Experiment 1 tested rimonabant-HU-210 interactions; Experiment 2 tested a dose range of HU-210. Licking burst patterns analyzed for reward and motor components.

What this study cannot tell us

Animal model using synthetic agonists; sucrose licking is a simplified model of feeding behavior; HU-210 is pharmacologically distinct from THC.

How to read the evidence

Single animal study with detailed behavioral microstructure analysis but using synthetic agonists.

When this study was published

Published in 2020.

The bigger picture

The finding that some cannabinoid agonists can reduce rather than increase feeding challenges simple narratives about cannabis and appetite, highlighting the importance of receptor pharmacology.

Questions still open

Would THC show similar motor impairment effects at high doses? Does the late-session rimonabant effect represent genuine reward devaluation?

Common questions

Don't cannabinoids usually increase appetite?

Generally yes, but the effects depend on the specific compound and dose. HU-210 is a potent non-selective cannabinoid agonist that, paradoxically, can reduce feeding. This study found the reduction was due to motor impairment rather than decreased reward value.

What does this tell us about rimonabant and weight loss?

Rimonabant (a CB1 antagonist previously used for weight loss before being withdrawn) appeared to reduce the reward value of sucrose when analyzed at the microstructural level, which could explain its appetite-suppressing effects.

Read the original research

Microstructure analysis of the effects of the cannabinoid agents HU-210 and rimonabant in rats licking for sucrose.

European journal of pharmacology, 887, 173468

View on PubMed ↗Publisher’s paper ↗

Citation

D'Aquila, Paolo S. (2020). Microstructure analysis of the effects of the cannabinoid agents HU-210 and rimonabant in rats licking for sucrose.. European journal of pharmacology, 887, 173468. https://doi.org/10.1016/j.ejphar.2020.173468